Lantheus/$LNTH
1D1W1MYTD1Y5YMAX
About Lantheus
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
- Ticker
- $LNTH
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,193
- Headquarters
- Bedford, United States
- Website
- www.lantheus.com
Lantheus Metrics
BasicAdvanced
$6.6B
24.29
$4.15
-0.03
-
Price and volume
Market cap
$6.6B
Beta
-0.03
52-week high
$111.86
52-week low
$49.67
Average daily volume
1.7M
Financial strength
Current ratio
3.06
Quick ratio
2.822
Long term debt to equity
47.589
Total debt to equity
43.533
Interest coverage (TTM)
15.33%
Profitability
EBITDA (TTM)
392.225
Gross margin (TTM)
60.14%
Net profit margin (TTM)
17.69%
Operating margin (TTM)
19.52%
Effective tax rate (TTM)
24.15%
Revenue per employee (TTM)
$1,300,000
Management effectiveness
Return on assets (TTM)
8.38%
Return on equity (TTM)
22.21%
Valuation
Price to earnings (TTM)
24.291
Price to revenue (TTM)
4.256
Price to book
5.02
Price to tangible book (TTM)
17.17
Price to free cash flow (TTM)
17.079
Free cash flow yield (TTM)
5.85%
Free cash flow per share (TTM)
5.906
Growth
Revenue change (TTM)
2.35%
Earnings per share change (TTM)
10.07%
3-year revenue growth (CAGR)
11.43%
10-year revenue growth (CAGR)
17.90%
3-year earnings per share growth (CAGR)
104.89%
10-year earnings per share growth (CAGR)
16.68%
What the Analysts think about Lantheus
Analyst ratings (Buy, Hold, Sell) for Lantheus stock.
Lantheus Financial Performance
Revenues and expenses
Lantheus Earnings Performance
Company profitability
Lantheus News
AllArticlesVideos
US FDA approves Lantheus' brain-imaging agent for Alzheimer's assessment
Reuters2 weeks ago
Lantheus Holdings to Be Acquired for Initial $6.7 Billion
WSJ3 weeks ago
LNTH Stock Alert: Halper Sadeh LLC is Investigating Whether Lantheus Holdings, Inc. is Obtaining a Fair Price for its Shareholders
Business Wire3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.